EKF Diagnostics Holdings PLC
LSE:EKF

Watchlist Manager
EKF Diagnostics Holdings PLC Logo
EKF Diagnostics Holdings PLC
LSE:EKF
Watchlist
Price: 25.7 GBX 1.98% Market Closed
Market Cap: 116.6m GBX
Have any thoughts about
EKF Diagnostics Holdings PLC?
Write Note

EKF Diagnostics Holdings PLC
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

EKF Diagnostics Holdings PLC
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
EKF Diagnostics Holdings PLC
LSE:EKF
Depreciation & Amortization
ÂŁ4.6m
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
1%
Smith & Nephew PLC
LSE:SN
Depreciation & Amortization
$659m
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Depreciation & Amortization
$44.1m
CAGR 3-Years
-7%
CAGR 5-Years
-9%
CAGR 10-Years
22%
Angle PLC
LSE:AGL
Depreciation & Amortization
ÂŁ2.2m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Depreciation & Amortization
ÂŁ3.5m
CAGR 3-Years
13%
CAGR 5-Years
47%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Depreciation & Amortization
$3.3m
CAGR 3-Years
214%
CAGR 5-Years
50%
CAGR 10-Years
N/A
No Stocks Found

EKF Diagnostics Holdings PLC
Glance View

Market Cap
116.6m GBX
Industry
Health Care

EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.

EKF Intrinsic Value
31.9 GBX
Undervaluation 19%
Intrinsic Value
Price

See Also

What is EKF Diagnostics Holdings PLC's Depreciation & Amortization?
Depreciation & Amortization
4.6m GBP

Based on the financial report for Jun 30, 2024, EKF Diagnostics Holdings PLC's Depreciation & Amortization amounts to 4.6m GBP.

What is EKF Diagnostics Holdings PLC's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
1%

Over the last year, the Depreciation & Amortization growth was -30%. The average annual Depreciation & Amortization growth rates for EKF Diagnostics Holdings PLC have been -4% over the past three years , 2% over the past five years , and 1% over the past ten years .

Back to Top